Details

Autor(en) / Beteiligte

• Zhu, Zewu
• Bo-Ran Ho, Bryan
• Chen, Alyssa
• Amrhein, James
• Apetrei, Andreea
• Carpenter, Thomas Oliver
• Lazaretti-Castro, Marise
• Colazo, Juan Manuel
• McCrystal Dahir, Kathryn
• Geßner, Michaela
• Gurevich, Evgenia
• Heier, Cathrine Alsaker
• Simmons, Jill Hickman
• Hunley, Tracy Earl
• Hoppe, Bernd
• Jacobsen, Christina
• Kouri, Anne
• Ma, Nina
• Majumdar, Sachin
• Molin, Arnaud
• Nokoff, Natalie
• Ott, Susan M.
• Peña, Helena Gil
• Santos, Fernando
• Tebben, Peter
• Topor, Lisa Swartz
• Deng, Yanhong
• Bergwitz, Clemens

Titel

An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH)

Ist Teil von

• Kidney international, 2024-05, Vol.105 (5), p.1058-1076

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Pathogenic variants in solute carrier family 34, member 3 (SLC34A3), the gene encoding the sodium-dependent phosphate cotransporter 2c (NPT2c), cause hereditary hypophosphatemic rickets with hypercalciuria (HHRH). Here, we report a pooled analysis of clinical and laboratory records of 304 individuals from 145 kindreds, including 20 previously unreported HHRH kindreds, in which two novel SLC34A3 pathogenic variants were identified. Compound heterozygous/homozygous carriers show above 90% penetrance for kidney and bone phenotypes. The biochemical phenotype for heterozygous carriers is intermediate with decreased serum phosphate, tubular reabsorption of phosphate (TRP (%)), fibroblast growth factor 23, and intact parathyroid hormone, but increased serum 1,25-dihydroxy vitamin D, and urine calcium excretion causing idiopathic hypercalciuria in 38%, with bone phenotypes still observed in 23% of patients. Oral phosphate supplementation is the current standard of care, which typically normalizes serum phosphate. However, although in more than half of individuals this therapy achieves correction of hypophosphatemia it fails to resolve the other outcomes. The American College of Medical Genetics and Genomics score correlated with functional analysis of frequent SLC34A3 pathogenic variants in vitro and baseline disease severity. The number of mutant alleles and baseline TRP (%) were identified as predictors for kidney and bone phenotypes, baseline TRP (%) furthermore predicted response to therapy. Certain SLC34A3/NPT2c pathogenic variants can be identified with partial responses to therapy, whereas with some overlap, others present only with kidney phenotypes and a third group present only with bone phenotypes. Thus, our report highlights important novel clinical aspects of HHRH and heterozygous carriers, raises awareness to this rare group of disorders and can be a foundation for future studies urgently needed to guide therapy of HHRH. [Display omitted]